Polaryx Therapeutics (NASDAQ: PLYX) provided an update on preparations for SOTERIA, its Phase 2 basket trial evaluating drug candidate PLX-200 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE